MobiHealth News June 8, 2023
Adam Ang

It is currently conducting an in-human trial of its diagnostic patch.

Diagnostics company Nutromics has raised A$11 million ($7 million) ahead of its Series A funding round later this year.

WHAT IT’S FOR

The company has been raising funds for the imminent commercialisation of its continuous diagnostic monitoring technology.

Established in 2017, Nutromics has been developing a “lab-in-a-patch,” which uses DNA sensor technology to track multiple targets, such as disease biomarkers and hard-to-dose drugs, in the human body. This technology is currently being tested in an in-human trial at Monash Health.

Aside from conducting clinical trials, the company is also setting up its R&D teams both in Australia and the United States.

THE LARGER TREND

The latest raise followed...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Digital Health, Investments, Technology, Trends
March Fundraising Roundup: 7 Provider Tech Startups That Closed Rounds This Month
Pelago Defies Digital Health Funding Drought, Raises $58M
Digital health venture capital deals stagnate
Finger on the Pulse: The State of Primary Care in the U.S. and Nine Other Countries
Embracing digital transformation with a digital factory

Share This Article